comparemela.com

Latest Breaking News On - Her2 nsclc - Page 1 : comparemela.com

DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.

Edwards kimTrastuzumab deruxtecanEvolving treatment landscapeFirst line trastuzumab deruxtecanNon small cell lung cancerHer2 nsclcHer2 mutated nsclcHer2 non small cell lung cancerAntibody drug conjugatesT dxdDestiny lung04

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

Experts on HER2 NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Trastuzumab deruxtecanEvolving treatment landscapeNon small cell lung cancerHer2 nsclcHer2 non small cell lung cancerAntibody drug conjugatesT dxdHer2 mutated nsclcHer2 mutated non small cell lung cancer

Role of ADCs in HER2-Mutated NSCLC

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

Evolving treatment landscapeNon small cell lung cancerHer2 nsclcHer2 non small cell lung cancerHer2 mutated nsclcAntibody drug conjugatesTreatment guidelinesTrastuzumab deruxtecan

vimarsana © 2020. All Rights Reserved.